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Abstract—Objective: To evaluate the association of incident dementia with mortality in a cohort of patients with
idiopathic PD who were nondemented at baseline evaluation, controlling for extrapyramidal sign (EPS) severity at each
study visit. Background: The development of dementia has been associated with reduced survival in PD. Because EPS
severity is associated with both dementia and mortality in PD, the association of dementia with mortality may be
confounded by disease severity. Methods: A cohort of patients with PD was followed annually with neurologic and
neuropsychological evaluations. The association of incident dementia and the total Unified PD Rating Scale (UPDRS)
motor score with mortality in PD was examined using Cox proportional hazards models with time-dependent covariates.
All analyses were adjusted for age at baseline, sex, years of education, ethnicity, and duration of PD. Results: Of 180 PD
patients, 41 (22.8%) died during a mean follow-up period of 3.9  2.2 years. Among those who died during the study
period, 48.8% (20 of 41) became demented during follow-up, as compared to 23.0% (32 of 139) of those who remained alive.
Both incident dementia (RR: 2.2, 95% CI: 1.1 to 4.5, p  0.04) and the total UPDRS motor score at each study visit (RR:
1.04, 95% CI: 1.02 to 1.07, p  0.001) were associated with mortality in PD when included in the same Cox model.
Conclusions: Incident dementia has an independent effect on mortality when controlling for EPS severity. The develop-
ment of dementia is associated with a twofold increased mortality risk in PD.
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The development of dementia has been associated
with reduced survival in patients with idiopathic
PD.1-5 Because severity of extrapyramidal signs
(EPS) is associated with both dementia6-9 and
mortality5,10-12 in PD, the association of dementia
with mortality in PD may be confounded by disease
severity as measured by EPS. We have previously
shown that when patients with PD were stratified by
EPS severity at baseline evaluation, the occurrence
of dementia at baseline or during follow-up contrib-
uted to mortality among those who had low EPS
score, but not among those who had high EPS score,
suggesting that EPS severity at baseline might be a
more important predictor of mortality than the de-
velopment of dementia.11
In the current study, we have examined the asso-
ciation of dementia with mortality in PD in the same
cohort, using a subsample of the patients and a dif-
ferent analytical approach. Because all patients were
nondemented at baseline evaluation, we assessed the
association of incident rather than prevalent demen-
tia with mortality in PD. The analysis controlled for
severity of EPS at each study visit, which takes into
account changes over time and provides a more accu-
rate assessment of the contribution of EPS severity
to mortality in PD.
Methods. Patients and procedures. A cohort of patients
with PD from the Washington Heights community in
northern Manhattan, NY, was followed annually, begin-
ning in 1988, with neurologic and neuropsychological eval-
uations. The ascertainment procedure and inclusion and
exclusion criteria for the cohort have been previously de-
scribed.13 Patients were identified through the develop-
ment of a registry for PD in the community for all
individuals considered to have PD or a related disorder.
This population-based PD cohort included, but was not
limited to, all patients living in the community who re-
ceived their care at the Columbia Presbyterian Medical
Center. Patients were identified from many sources includ-
ing admission and discharge lists from the hospital, lists
from various ambulatory care sites, and practitioners both
in the hospital and in the community.
Idiopathic PD was defined by clinical and research
criteria.14-16 Patients with postencephalitic and drug-
induced parkinsonism or a Parkinson-plus syndrome were
excluded, as were patients who presented memory loss or
dementia before the motor manifestations of PD. Of 319
patients with idiopathic PD, 105 considered to be de-
mented at baseline evaluation were excluded from this
analysis. Of 214 nondemented patients, 31 had no
follow-up visit. These 31 patients with no follow-up were
less likely to be white/non-Hispanic (25.8% vs 54.6%, p 
0.05) than the patients with follow-up (n  183). No signif-
icant differences were observed for age, sex, years of edu-
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cation, duration of PD, or severity of EPS. Three additional
patients were excluded because they had signs or symp-
toms of stroke at baseline, leaving 180 patients with at
least two visits for the current analysis. Duration of PD
was defined as the time period between the first symptom
of PD and the baseline evaluation.
Data collection was performed blind to data collected in
previous visits and dementia status. The annual clinical
evaluation included parts I (mentation, behavior, and
mood), II (activities of daily living), and III (motor exami-
nation) of the Unified PD Rating Scale (UPDRS).17 Use of
antiparkinsonian medications, presence of signs or symp-
toms of stroke, and history of hypertension, diabetes melli-
tus, or heart disease (including myocardial infarction,
congestive heart failure, valvular heart disease, angina,
atrial fibrillation, or other cardiac arrhythmias) were re-
corded at each study visit. The validity of reporting of
hypertension, diabetes mellitus, and heart disease com-
pared to medical chart information has been examined in
the same community.18
The annual neuropsychological evaluation included
tests of verbal and nonverbal memory, orientation, visuo-
spatial ability, language, and abstract reasoning.19 Neuro-
psychological test scores were evaluated using a fixed
paradigm19 and dementia was diagnosed based on the cri-
teria of the Diagnostic and Statistical Manual of Mental
Disorders, revised third edition (DSM-III-R).20 Each pa-
tient was assigned a Clinical Dementia Rating (CDR)21 at
each study visit. Nondemented patients had either CDR 0
(no dementia) or CDR 0.5 (questionable dementia),
whereas demented patients were assigned CDR scores of 1
or more. Information about where subject was living
(home, nursing home, hospital, rehabilitation center,
other) was collected at each study visit. Death information
was obtained from the following sources: family, hospital
records, death certificates, autopsy reports, and death
records of the National Death Index. Causes of death were
known for 20 out of the 41 deceased patients during the
study period.
Data analysis. Baseline characteristics of patients
who died and those who remained alive during the study
period were compared using Student’s t-test for continuous
variables and 2 test or Fisher exact test for categorical
variables. The association of incident dementia with mor-
tality in PD was analyzed using Cox proportional hazards
models with time-dependent covariates.22 Duration of
follow-up from baseline until death or until the last visit
for those patients who remained alive during the study
period was used as the timing variable in the Cox models.
All analyses adjusted for age at baseline, sex, years of
education, ethnicity, and duration of PD. The Cox propor-
tional hazards model with time-dependent covariates
takes into account changes in predictor variables at each
study visit (e.g., a patient may be nondemented at the first
two visits and demented at the third visit or a patient may
have a total UPDRS motor score of 10 at one visit and 15
at a subsequent visit). Because all patients were nonde-
mented at baseline evaluation, any patient who met DSM-
III-R criteria for dementia at any study visit represents an
incident dementia case.
The total UPDRS motor score (range: 0 to 100) was
calculated by summing the ratings (range: 0 [absent or
normal] to 4 [most severe impairment]) of 25 items of the
UPDRS motor examination (part III). We also analyzed
the association of six motor domains of the UPDRS with
mortality in PD. The six motor domains included facial
expression, tremor, rigidity, bradykinesia, speech, and ax-
ial impairment (gait, postural stability, posture, arising
from a chair).23 Although the grouping of the items of the
UPDRS motor examination to six domains was based on
the cardinal clinical manifestations of PD rather than on a
data-driven approach, a principal component factor analy-
sis (varimax rotation) produced six factors with eigenval-
ues greater than 1 that broadly corresponded to the
clinically defined motor domains.
In supplementary analyses, we evaluated other factors
that might confound the association of incident dementia
with mortality in PD as time-dependent covariates. These
factors included medication use, vascular disease, nursing
home placement, hallucinations, and depressive symp-
toms. For hallucinations and depressive symptoms, we de-
fined categorical variables based on cutoff values of the
ratings (range: 0 [none or normal] to 4 [most severe im-
pairment]) of the items thought disorder and depression of
the UPDRS (part I). Two categorical variables were de-
fined for each item based on a more or less stringent cutoff
value. Thought disorder (1) was considered to be present if
a patient had a rating of 2 (“‘benign’ hallucinations with
insight retained”) or more, and thought disorder (2) was
considered to be present if a patient had a rating of 3
(“occasional to frequent hallucinations or delusions; with-
out insight; could interfere with daily activities”) or more.
Depression (1) was considered to be present if a patient
had a rating of 2 (“sustained depression [1 week or more]”)
or more, and depression (2) was considered to be present if
a patient had a rating of 3 (“sustained depression with
vegetative symptoms [insomnia, anorexia, weight loss, loss
of interest]”) or more.
In the Cox model with time-dependent covariates, a
missing value for a time-dependent covariate in one study
visit leads to the complete loss of the case in the analysis.
In order to prevent missing the total information provided
by a case due to a missing value for a variable in one
annual visit, we carried over information on a categorical
variable (e.g., dementia) of the previous visit to the visit
with missing information. For continuous variables (e.g.,
total UPDRS motor score), we input the mean of the previ-
ous and subsequent visits. For each time-dependent co-
variate, the proportion of missing data ranged from 5 to
10% of the total number of visits for all patients in the
cohort (895 visits).
Results. Of 180 patients with PD, 41 (22.8%) died during
a mean follow-up period of 3.9  2.2 years. Patients who
died during the study period were significantly older, less
often Hispanic, and had higher total UPDRS motor score
at baseline evaluation than those who remained alive. His-
tory of heart disease and ever smoking were significantly
more frequent among those who died. Use of selegiline at
baseline was not reported among those who died and was
reported by 12.9% of those who remained alive (Fisher
exact test, p  0.01). Estrogen replacement therapy in
women was not reported among those who died and was
reported by 17.7% of those who remained alive (Fisher
exact test, p  0.07) (table 1). Fifty-two (28.9%) patients
became demented during follow-up. Among those who
died, 48.8% (20 of 41) became demented during follow-up,
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as compared to 23.0% (32 of 139) of those who remained
alive (2 test, p  0.001).
In a Cox model adjusting for age at baseline, sex, years
of education, ethnicity, and duration of PD, incident de-
mentia was associated with an increased mortality risk
(RR: 3.7, 95% CI: 2.0 to 7.2, p  0.001). When we included
the CDR score at each study visit instead of incident de-
mentia in the model, we observed increasing mortality risk
with higher CDR score. In a separate model, the total
UPDRS motor score at each study visit was also associated
with an increased mortality risk (RR: 1.06, 95% CI: 1.03 to
1.08, p  0.001). When both incident dementia and EPS
severity were analyzed in a Cox model, both incident de-
mentia (RR: 2.2, 95% CI: 1.1 to 4.5, p  0.04) and the total
UPDRS motor score at each study visit (RR: 1.04, 95% CI:
1.02 to 1.07, p  0.001) were associated with mortality in
PD (table 2, models 1 to 4).
Among the specific motor domains of the UPDRS (facial
expression, tremor, rigidity, bradykinesia, speech, and ax-
ial impairment), all except tremor were significantly asso-
ciated with mortality in PD when included in separate Cox
models. However, when included in the same model, only
axial impairment was significantly associated with mortal-
ity in PD. When we reevaluated the association of incident
dementia with mortality in PD controlling for axial impair-
ment, incident dementia was still associated with a twofold
increased mortality risk, but this result did not reach sig-
nificance (see table 2, models 5 and 6).
Supplementary analysis. We performed supplemen-
tary analyses designed to evaluate other possible con-
founders in the association of incident dementia with
mortality in PD. To explore the possibility that the associ-
ation of dementia with mortality was related to with-
drawal of levodopa (due to increased psychiatric side
effects)24 or to a hypothetical protective effect of selegiline
on disease progression,25,26 which might both delay the de-
velopment of dementia and increase survival, we repeated
the analysis controlling for use of levodopa and use of
selegiline as time-dependent covariates in different mod-
els. However, neither use of levodopa nor use of selegiline
accounted for the association of incident dementia with
mortality in PD.
The association of incident dementia with mortality was
unchanged when signs or symptoms of stroke and history
Table 1 Baseline demographic and clinical characteristics of patients with PD who died during the study period and those who
remained alive
Variable Deceased, n  41 Alive, n  139 Total, n  180
Age, y* 75.9 (8.7) 69.6 (10.3) 71.0 (10.3)
Education, y 10.8 (4.6) 11.2 (4.8) 11.1 (4.8)
% Male 58.5 42.4 46.1
Ethnicity, %*
White non-Hispanic 68.3 51.8 55.6
Black non-Hispanic 14.6 7.2 8.9
Hispanic 17.1 41.0 35.6
Primary language, % English* 80.0 56.5 61.8
Duration of PD, y 7.6 (8.8) 5.9 (6.2) 6.3 (6.9)
Total UPDRS motor score, range 0–100* 30.4 (15.1) 23.4 (11.6) 25.0 (12.8)
Total 17-item HDRS score, range 0–53 7.5 (5.9) 5.6 (4.8) 6.1 (5.1)
Use of levodopa, % 63.4 75.5 72.8
Use of dopaminergic agonists, % 35.0 26.1 28.1
Use of anticholinergics, % 13.5 16.5 15.9
Use of selegiline, %* 0 12.9 10.0
Levodopa dosage, mg/d 377.1 (484.8) 347.4 (317.4) 354.1 (360.6)
Hypertension, % 41.5 36.7 37.8
Diabetes mellitus, % 10.0 8.0 8.4
Heart disease, %*† 53.7 20.1 27.8
Ever smoking, %* 60.0 40.1 44.6
At least one APOE ε4 allele, % 22.7 23.4 23.3
Estrogen replacement therapy, %* 0 17.7 14.6
Values are mean (SD) or %. Total n: 178 for language, 177 for UPDRS score, 154 for HDRS score, 178 for use of dopaminergic agonists,
176 for use of anticholinergics, 159 for levodopa dosage, 178 for diabetes mellitus, 177 for ever smoking, 133 for APOE genotype, and
96 for estrogen replacement therapy.
* p  0.05 for the comparison deceased vs alive.
† Includes myocardial infarction, congestive heart failure, valvular heart disease, angina, atrial fibrillation, and other cardiac
arrhythmias.
UPDRS  Unified Parkinson’s Disease Rating Scale; HDRS  Hamilton Depression Rating Scale.
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of hypertension, diabetes mellitus, or heart disease were
included in the same Cox model. Because we have previ-
ously shown an association of smoking with incident de-
mentia in PD18 and smoking was significantly more
frequent in those who died compared to those who re-
mained alive during the study period (see table 1), we
repeated the analysis controlling for baseline information
regarding smoking (ever vs never and current and past vs
never). In this analysis, incident dementia was still signif-
icantly associated with mortality in PD and the strength of
the association was similar. The frequency of having at
least one APOE 4 allele was similar in patients with PD
who died and those who remained alive during the study
period (see table 1), and the association of incident demen-
tia with mortality did not change when the analysis was
repeated controlling for this variable.
An association between nursing home placement and
mortality in PD has been reported.27 In our cohort, only 6
out of 180 patients (3.3%) lived in a nursing home at any
time during the study period (one patient since the base-
line study visit and one patient temporarily for one study
visit). Of these, four were cases with incident dementia
and two died during the study period (both with incident
dementia). When nursing home placement and incident
dementia were included in a Cox model as time-dependent
covariates, the association of incident dementia with mor-
tality in PD did not change.
Neither the thought disorder nor the depression item
from the UPDRS (part I) was significantly associated with
dementia in PD using both definitions (see Methods), and
the association of incident dementia with mortality in PD
did not change when controlling for thought disorder and
depression as time-dependent covariates. A subset of the
cohort was evaluated with the Hamilton Depression Rat-
ing Scale.28 There was no significant difference in the total
Hamilton Depression Rating Scale score at baseline be-
tween patients with PD who died and those who remained
alive during the study period (see table 1), and the inclusion
of this variable in a Cox model did not substantially change
the association of incident dementia with mortality in PD.
Discussion. In this study, the development of de-
mentia was associated with a twofold increased mor-
tality risk in PD, after controlling for the total
UPDRS motor score at each study visit. Incident de-
mentia had an independent effect on mortality when
controlling for disease severity as measured by EPS
and other factors that might confound the association
of dementia with mortality in PD such as medication
use, vascular disease, nursing home placement, hallu-
cinations, and depressive symptoms. The finding of in-
dependent effects of EPS severity and dementia on
mortality in PD mirrors the observation of independent
effects of parkinsonian signs and severity of cognitive
impairment on mortality in AD.29-31 The association of
axial motor impairment with mortality in PD is consis-
tent with previous studies showing decreased survival
in patients with PD with gait and postural impairment
or who had reached Hoehn & Yahr stage III.3,5,12 This
finding is also supported by studies showing an associ-
ation of gait impairment32,33 and falls34 with mortality
in the elderly. When axial impairment was adjusted for
in the analysis, the risk for dementia was twofold, but
not significant (p  0.07). We believe this may be due
to limited statistical power in this study.
Some studies have evaluated the association of
dementia with mortality in PD while controlling for
EPS severity at baseline only.3,4,11,35 In a study fol-
lowing 34 patients with PD with cognitive impair-
ment matched by age, sex, disease duration, and
disease severity to 34 patients without cognitive im-
pairment for 7 years, 33.3% of those with intellectual
impairment and 12.5% of those without cognitive im-
pairment died during follow-up, and a significantly
higher percentage of deaths were observed in pa-
tients with more severe dementia.4 In two multivari-
ate analyses of predictors of mortality in PD,
cognitive impairment as measured by a 10-question
mental status questionnaire was a significant predic-
tor of mortality in a community-based study in Aber-
deen, Scotland,3 whereas dementia was not a
significant predictor of mortality in the context of a
multicenter clinical trial in Sydney, Australia.35
Before levodopa therapy became available, PD
had been associated with a threefold increased mor-
tality compared to controls.36 Studies performed on
cohorts of patients with PD on levodopa therapy
have produced conflicting results. Some studies have
Table 2 Association of incident dementia with mortality in PD
controlling for the UPDRS motor examination (part III)*
Model
Time-dependent
covariates RR (95% CI) p Value
1 Incident dementia 3.7 (2.0 to 7.2) 0.001
2 CDR 0 (reference) 1 —
CDR 0.5 (questionable
dementia)
1.2 (0.4 to 3.5) 0.7
CDR 1 3.6 (1.6 to 8.2) 0.002
CDR 2 4.3 (1.4 to 13.8) 0.01
CDR 3 or 4 5.0 (1.8 to 14.0) 0.002
3 Total UPDRS motor
score
1.06 (1.03 to 1.08) 0.001
4 Incident dementia 2.2 (1.1 to 4.5) 0.04
Total UPDRS motor
score
1.04 (1.02 to 1.07) 0.001
5 Speech 1.37 (0.88 to 2.14) 0.2
Facial expression 0.80 (0.48 to 1.34) 0.4
Tremor 1.00 (0.91 to 1.09) 0.9
Rigidity 1.06 (0.96 to 1.17) 0.3
Bradykinesia 1.04 (0.97 to 1.13) 0.3
Axial impairment 1.12 (1.01 to 1.25) 0.03
6 Incident dementia 2.0 (0.9 to 4.4) 0.07
Axial impairment 1.16 (1.06 to 1.26) 0.001
* All analyses adjusted for age at baseline, sex, years of educa-
tion, ethnicity, and duration of PD.
CDR  Clinical Dementia Rating; UPDRS  Unified Parkinson’s
Disease Rating Scale.
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shown no increased mortality risk compared to
controls,37-42 whereas several other studies have dem-
onstrated that patients with PD are at a 1.5 to 3.5
times significantly increased mortality risk com-
pared to controls.10,11,35,43-53 It has been suggested that
normal or near to normal mortality ratios in early
studies following the introduction of levodopa ther-
apy was due to levodopa delaying death in a group of
older patients with PD.54 The range in mortality
risks in different cohorts may also depend on disease
severity and inclusion of demented patients.
Our study has limitations. The cohort consisted of
individuals with a mean age at baseline of 71.0 
10.3 years and the findings may not be applicable to
a cohort of younger patients. Exclusion of patients
with incomplete follow-up might have introduced a
bias in the study sample, but no significant differ-
ences in age, sex, education, duration of PD, or EPS
severity were observed between those with only the
baseline evaluation and those with at least one
follow-up visit. By including only incident dementia
cases in our analysis, we were able to take into ac-
count the timing of the development of dementia in
relation to mortality and to control for EPS severity
at the time dementia developed. Conversely, by ex-
cluding cases without a dementia-free interval before
the baseline evaluation, we may have excluded some
cases with more rapidly progressive disease. We con-
trolled for hallucinations and depressive symptoms
using a four-point rating from the UPDRS (part I)
rather than a comprehensive assessment of psychiat-
ric symptomatology. Whereas previous studies have
shown an association of depressive symptoms and
hallucinations with dementia in PD,6,7 a recent study
using the Rush Hallucination Inventory found no
significant association of hallucinations with mortal-
ity in PD.55
In a mortality study performed after levodopa be-
came available, patients with PD who eventually
died benefited less from levodopa therapy than those
who survived.10 Our finding that axial (gait and pos-
tural) impairment and dementia were associated
with mortality in PD supports the suggestion that
once non-levodopa responsive clinical characteristics
appear, mortality in PD rises.35 Although the mecha-
nism underlying the association of dementia with
mortality in PD is unclear, we speculate that a wide-
spread pathologic process involving both dopaminer-
gic and nondopaminergic structures in late stages of
the disease underlies dementia23 as well as swallow-
ing56 and autonomic57 dysfunction in PD.
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